Emerging role of baricitinib in dermatology practice: All we need to know!
Baricitinib is a competitive inhibitor of the Janus Kinase family of non-receptor protein kinases, predominantly acting against JAK-1 and JAK-2 subtypes. By downregulating transcription of various pro-inflammatory cytokines, this drug has shown efficacy across various dermatoses. Approved for severe...
Saved in:
Main Authors: | Sunil Dogra (Author), Shikha Shah (Author), Ayush Sharma (Author), Seema Chhabra (Author), Tarun Narang (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Abrocitinib: A Comprehensive Review of its Efficacy and Safety in Dermatology
by: Sunil Dogra, et al.
Published: (2024) -
Mycobacterium indicus pranii (MIP) vaccine: Pharmacology, indication, dosing schedules, administration, and side effects in clinical practice
by: Sunil Dogra, et al.
Published: (2023) -
Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022) -
Emerging atypical and unusual presentations of dermatophytosis in India
by: Sunil Dogra, et al.
Published: (2017) -
Inflammasome Related Mediators and Their Association with Disease Determinants in Chronic Plaque Psoriasis
by: Seema Chhabra, et al.
Published: (2021)